Aurion doses first patients in US Phase 1/2 clinical trial

Seattle-based company Aurion Biotech announced that a subject in its Phase 1/2 clinical trial was the first to receive a dose of its corneal endothelial cell therapy, AURN001. The development follows AURN001’s recent approval in Japan, one of the company’s three locations.

The trial will provide insights into the safety, success and patient response to the treatment, which is meant to be a one-time injection into the front chamber of a patient’s eye. 

“The start of this trial is another important milestone in our goal of bringing this corneal endothelial cell therapy to millions of patients in need throughout the world,” said Michael Goldstein, MD, Aurion Biotech’s president and chief medical officer. “We believe that cell therapy has the potential to revolutionize the treatment of corneal patients around the world.”

READ THE STORY at Ophthalmology Times »